Although anti-VEGF therapy has several clinical benefits, its monthly requirement potentially causes devastating ocular complications, including trauma, intraocular hemorrhage, retinal detachment, endophthalmitis, etc. A treatment that could reduce monthly intravitreal injection frequency is well considered for clinical applications. Here, VEGFA is linked to retinal detachment.